Related Experiment Video
Updated: Jun 22, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Permanent iodine-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies
Subhakar Mutyala1, Alexandra Stewart, Atif J Khan
1Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine in 1625 Poplar St., Bronx, New York, 10461, USA. smutyala@montefiore.org
Purpose:
To assess toxicity and outcome following permanent iodine-125 seed implant as an adjunct to surgical resection in cases of advanced thoracic malignancy.
Methods And Materials:
An institutional review board-approved retrospective review was performed. Fifty-nine patients were identified as having undergone thoracic brachytherapy seed implantation between September 1999 and December 2006. Data for patient demographics, tumor details, and morbidity and mortality were recorded.
Results:
Fifty-nine patients received 64 implants. At a median follow-up of 17 months, 1-year and 2-year Kaplan-Meier rates of estimated overall survival were 94.1% and 82.0%, respectively. The 1-year and 2-year local control rates were 80.1% and 67.4%, respectively. The median time to develop local recurrence was 11 months. Grades 3 and 4 toxicity rates were 12% at 1 year.
Conclusions:
This review shows relatively low toxicity for interstitial planar seed implantation after thoracic surgical resection. The high local control results suggest that an incomplete oncologic surgery plus a brachytherapy implant for treating advanced thoracic malignancy merit further investigation.
